PBAC to consider semaglutide listing for weight loss
The drug is still not marketed in Australia despite being registered last September.
![](https://www.ausdoc.com.au/wp-content/uploads/2023/07/iStock-1075575838-weight-300x225.jpg)
Novo Nordisk has applied for PBS funding for its subcutaneous weight loss drug Wegovy as a severe obesity treatment.
The product contains the GLP-1 receptor agonist semaglutide — the same active ingredient as Ozempic — and was approved by the TGA in September last year for adults with obesity, or overweight in the presence of at least one weight-related comorbidity.